The Supreme Court has upheld a ruling in the Tel Aviv District Court.
Ben Gurion University researcher Dr. Tomer Hertz says flu jabs, like vaccinations against childhood diseases, are a social act that helps prevent infecting others.
The Israeli company's healthcare analytics platform delivers improved clinical and operational outcomes by predicting life-threatening complications.
The company develops next-generation gene editing using synthetic biology to address untreatable diseases.
The US medical device company will pay close to the $60 million that LifeBond has raised from investors.
BioProtect's ProSpace balloon spacer protects prostate cancer patients undergoing radiation therapy.
Last year, Motixafortide received Orphan Drug Designation for the treatment of Pancreatic Cancer from the US Food and Drug Administration (FDA).
At the JP Morgan Healthcare Conference, Teva CEO Kare Schultz said the company was on target with streamlining and debt reduction, and outlined its strategy for the Chinese market.
Dr. Daniel Drai's startup has patented a cocktail of drugs to prevent premature ejaculation. He says the market could be bigger than that of Viagra.
VP discovery David Wilson tells "Globes" that Teva is still an innovative company and has turned its attention back to Israel in the search for new drug candidates.
Two former Teva sales representatives told how doctors were paid to prescribe branded drugs Copaxone and Azilect.
Koch Industries will become the controlling shareholder in the Israeli MRI guided ultrasound company.
Koch Industries already owns 17% of the shares in Insightec.
The company has developed a way of precisely adapting antibiotics to infections.
The ARC center fosters local and international collaboration for digital healthcare projects, with on the spot input from doctors and nurses.
Teva looks to China